FMC Prepares for Sept. 10 Jefferies Conference: A Cleaner Balance Sheet Meets Crop-Science Ambition -( $FMC )

FMC Corporation (NYSE: FMC) heads into the 2026 Jefferies Global Industrials Conference with a story that is no longer about simply enduring a difficult crop-protection cycle. It is increasingly about balance-sheet repair, portfolio renewal and the possibility that a battered agricultural-sciences franchise is building the ingredients for a more credible earnings recovery. Chairman, CEO and President Pierre Brondeau and CFO Andrew Sandifer are scheduled to present on September 10 at 11:30 a.m. Eastern. For many, the event offers a timely opportunity to hear how management intends to convert a year of aggressive restructuring and asset monetization into a cleaner, more competitive FMC. In agriculture, as in investing, the harvest generally comes after the field has been worked, not after the first optimistic weather report.

A Reset With Real Financial Tools

The most constructive aspect of the FMC investment case is that management has paired its turnaround language with tangible financial actions. During the second quarter, the company outlined roughly $1 billion in anticipated proceeds earmarked for debt reduction, an important effort for a company facing both cyclical pricing pressure and elevated interest expense. The planned sources of capital include:

• A definitive agreement to sell FMC’s India commercial business for $252 million.
• A licensing agreement involving rimisoxafen that delivered a $200 million upfront payment from Corteva, Inc. (NYSE: CTVA).
• A $114 million sale-leaseback transaction involving FMC’s Newark, Delaware property.
• A planned $400 million equity investment from Tessenderlo Group, subject to customary closing conditions and approvals.

Together, those actions are designed to reduce leverage, increase operating flexibility and allow FMC to focus capital on the technology platforms that management believes can power the next phase of growth. The Board has also concluded its strategic review, giving the company a clearer mandate: execute the operating plan rather than keep the “For Sale” sign hanging in the window indefinitely.

Cash Flow Is the Early Proof Point

The headline earnings figures remain challenged, but cash generation offered a more encouraging signal in the second quarter. FMC reported $363 million in GAAP operating cash flow and $357 million in free cash flow, aided materially by the $200 million rimisoxafen licensing payment. That does not erase the pressure on underlying earnings, but it does reinforce the practical value of the company’s intellectual property. For many, this distinction matters. A turnaround is not validated by an inspirational slide deck or an unusually confident conference microphone. It is validated when a company can monetize assets, improve liquidity and preserve the ability to invest in future growth while the current market remains demanding. FMC appears to be moving in that direction.

The Growth Portfolio Offers a Better Narrative

FMC’s core legacy portfolio still faces pricing pressure, especially as growers manage tight farm economics and the company navigates the post-patent transition of Rynaxypyr. Yet the more compelling part of the story sits within the growth portfolio. In the first quarter, FMC said sales of new active ingredients doubled year over year, while Plant Health sales grew 6%. Management had previously projected $300 million to $400 million in 2026 sales from new active ingredients, representing more than 75% growth at the midpoint of its original outlook. The company highlighted products and platforms including Isoflex, fluindapyr and Dodhylex, alongside continued growth ambitions for Cyazypyr and newer Rynaxypyr formulations. By the second quarter, FMC said its growth portfolio expanded by a mid-single-digit percentage, as strong performance from new active ingredients and Cyazypyr more than offset weaker Plant Health sales. Branded Rynaxypyr sales were essentially flat excluding India, supported by demand for new formulations. That is a meaningful operational clue: the legacy platform may be under pressure, but the portfolio is not standing still politely waiting for the pressure to disappear.

Fourth-Quarter Growth Could Change the Conversation

FMC lowered its full-year 2026 outlook in July, reflecting a more difficult macro backdrop, continued pricing pressure and lower diamide-partner orders. The company now expects full-year revenue excluding India of $3.50 billion to $3.70 billion, adjusted EBITDA of $620 million to $680 million, adjusted EPS of $1.19 to $1.49 and free cash flow of $75 million to $225 million. That guidance reset is not a bullish data point by itself. The more interesting element is the company’s expectation of a return to year-over-year growth in the fourth quarter. FMC forecasts fourth-quarter revenue excluding India of $1.06 billion to $1.20 billion, a 4% increase at the midpoint versus the prior-year period. Adjusted EBITDA is projected at $275 million to $315 million, a 5% midpoint increase. The anticipated improvement is expected to be driven by stronger direct-to-grower sales in Brazil, new active ingredients and North American distributor purchases that shift from the third quarter into the fourth. If that outlook holds, the market could begin treating FMC less as a company in free fall and more as a recovery candidate with identifiable operational milestones. Wall Street does enjoy a good comeback story, provided, of course, that the sequel includes numbers rather than merely better lighting.

Why the Jefferies Event Matters

The September presentation gives FMC an important platform to address questions that are central to the stock’s re-rating potential:

• How quickly will the approximately $1 billion debt-reduction program close and reduce leverage?
• What are the near-term margin implications of Project Foundation and other cost actions?
• Can growth in new active ingredients increasingly offset price declines and legacy-product softness?
• How durable is the fourth-quarter recovery thesis across Brazil, North America and other key markets?
• What is the longer-term earnings runway as FMC advances its pipeline of crop-protection technologies, biologicals, precision agriculture and digital tools?

FMC describes itself as a global agricultural-sciences company serving growers of food, feed, fiber and fuel through crop-protection, biological, nutrition and precision-agriculture solutions. The company’s opportunity is to translate that technology base into a growth profile that is less dependent on any one mature active ingredient and more resilient across geographies and agricultural cycles.

The Bull Case for FMC Stock

The bullish thesis for FMC (NYSE: FMC) is not that the company has already completed its turnaround. It plainly has work left to do, including managing lower pricing, soft legacy demand, execution risk around its asset transactions and a still-challenging agricultural economy. Rather, the opportunity lies in the possibility that FMC is building a sturdier foundation before the market fully recognizes it:

• Debt reduction could improve financial flexibility and ease a key investor concern.
• Asset monetization demonstrates that FMC’s portfolio has strategic and financial value.
• New active ingredients and differentiated technologies provide a potential growth engine beyond mature products.
• Cost restructuring could create meaningful operating leverage if volumes stabilize and growth products gain scale.
• The company’s own fourth-quarter outlook points to a potential inflection in revenue and adjusted EBITDA growth.

For patient investors, FMC may represent a classic “show-me” recovery story: one where the valuation debate will likely turn not on the next quarter’s bruises, but on whether management can deliver the promised cash flow, balance-sheet progress and product-led growth in the quarters that follow. The upcoming Jefferies Global Industrials Conference will not settle every question. But it may offer a more refined picture of whether FMC Corporation (NYSE: FMC) is merely pruning the garden—or preparing it for a far more profitable growing season.

The Sources

1. FMC Corporation CEO Pierre Brondeau and CFO Andrew Sandifer to Speak at the 2026 Jefferies Global Industrials Conference FMC Investor Relations
2. FMC Corporation Reports Second-Quarter 2026 Results With Adjusted EBITDA Above the High End of Guidance Range and Solid Cash Generation PR Newswire
3. FMC Corporation Reports First-Quarter 2026 Results Above Guidance With Adjusted EBITDA Above the High End of Range FMC Investor Relations
4. FMC Corporation CEO Pierre Brondeau and CFO Andrew Sandifer to Speak at the 2026 Jefferies Global Industrials Conference Yahoo Finance
5. FMC Corporation Investor Relations
6. FMC Corporation SEC Filings
7. FMC Corporation Official Corporate Website

Disclosure: This material is for informational purposes only and is not investment advice, a recommendation to buy or sell securities, or a solicitation of an offer. Investors should review FMC’s SEC filings, earnings materials and risk factors before making an investment decision.